Various biomarkers, such as the expression of programmed death ligand-1 (PD-L1), the microsatellite instability (MSI) status, tumor mutational burden (TMB), and Epstein–Barr virus (EBV) infection, demonstrate potential to predict the effectiveness of immunotherapy in treating GC. This evidence concerns the gene CD274 and Epstein-Barr virus infection.